Vimta Labs (VIMTALABS) | Financial Analysis & Statements
Vimta Labs Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
975.6M
Gross Profit
787.6M
80.72%
Operating Income
238.3M
24.42%
Net Income
188.9M
19.37%
EPS (Diluted)
₹4.21
Balance Sheet Metrics
Total Assets
4.7B
Total Liabilities
876.8M
Shareholders Equity
3.8B
Debt to Equity
0.23
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Vimta Labs Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.4B | 3.2B | 3.2B | 2.8B | 2.1B |
| Cost of Goods Sold | 714.5M | 762.8M | 738.5M | 792.0M | 611.1M |
| Gross Profit | 2.7B | 2.4B | 2.4B | 2.0B | 1.5B |
| Gross Margin % | 79.2% | 76.0% | 76.6% | 71.3% | 70.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 92.3M | 109.8M | 115.2M | 89.0M | 79.2M |
| Other Operating Expenses | 391.4M | 380.9M | 387.0M | 252.0M | 196.0M |
| Total Operating Expenses | 483.7M | 490.7M | 502.2M | 341.0M | 275.2M |
| Operating Income | 906.0M | 575.1M | 696.8M | 633.7M | 360.2M |
| Operating Margin % | 26.3% | 18.1% | 22.1% | 23.0% | 17.3% |
| Non-Operating Items | |||||
| Interest Income | 15.7M | 13.4M | 12.0M | 8.3M | 4.1M |
| Interest Expense | 13.9M | 15.2M | 9.3M | 8.3M | 17.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 890.0M | 544.8M | 650.0M | 556.8M | 285.4M |
| Income Tax | 222.4M | 134.7M | 168.2M | 143.6M | 71.4M |
| Effective Tax Rate % | 25.0% | 24.7% | 25.9% | 25.8% | 25.0% |
| Net Income | 673.4M | 410.1M | 481.7M | 413.3M | 214.0M |
| Net Margin % | 19.6% | 12.9% | 15.3% | 15.0% | 10.3% |
| Key Metrics | |||||
| EBITDA | 1.3B | 935.3M | 1.0B | 866.7M | 586.6M |
| EPS (Basic) | ₹15.14 | ₹18.51 | ₹21.77 | ₹18.70 | ₹9.68 |
| EPS (Diluted) | ₹14.93 | ₹18.24 | ₹21.35 | ₹18.32 | ₹9.68 |
| Basic Shares Outstanding | 44469024 | 22150331 | 22128989 | 22107810 | 22107810 |
| Diluted Shares Outstanding | 44469024 | 22150331 | 22128989 | 22107810 | 22107810 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vimta Labs Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 158.4M | 134.4M | 305.0M | 108.0M | 61.9M |
| Short-term Investments | 168.8M | 121.6M | 90.7M | 4.1M | 3.9M |
| Accounts Receivable | 1.1B | 870.0M | 799.9M | 769.2M | 734.6M |
| Inventory | 250.6M | 246.9M | 226.2M | 173.8M | 146.4M |
| Other Current Assets | 100.8M | 100.8M | 100.8M | 83.7M | 75.5M |
| Total Current Assets | 1.9B | 1.6B | 1.6B | 1.2B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 89.4M | 32.3M | 32.3M | 32.3M | 32.3M |
| Goodwill | 64.2M | 202.5M | 233.6M | 245.2M | 111.6M |
| Intangible Assets | 64.2M | 90.9M | 122.0M | 133.6M | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 20.5M | 21.8M | 41.8M | 92.5M | 20.0K |
| Total Non-Current Assets | 2.8B | 2.4B | 2.0B | 1.8B | 1.6B |
| Total Assets | 4.7B | 4.0B | 3.6B | 3.1B | 2.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 104.9M | 82.3M | 144.4M | 123.4M | 148.3M |
| Short-term Debt | 52.9M | 101.2M | 51.0M | 66.8M | 161.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 15.0M | 8.4M | 8.5M | 8.5M | 3.4M |
| Total Current Liabilities | 643.7M | 540.7M | 572.8M | 477.5M | 539.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 32.2M | 90.7M | 98.9M | 126.6M | 142.4M |
| Deferred Tax Liabilities | 0 | 780.0K | 690.0K | 740.0K | 700.0K |
| Other Non-Current Liabilities | 82.2M | 53.3M | 45.2M | 55.8M | 38.4M |
| Total Non-Current Liabilities | 233.2M | 262.8M | 232.6M | 254.6M | 260.6M |
| Total Liabilities | 876.8M | 803.5M | 805.4M | 732.1M | 799.8M |
| Equity | |||||
| Common Stock | 44.5M | 44.3M | 44.3M | 44.2M | 44.2M |
| Retained Earnings | 2.8B | 2.2B | 1.9B | 1.4B | 1.1B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.8B | 3.2B | 2.8B | 2.3B | 1.9B |
| Key Metrics | |||||
| Total Debt | 85.2M | 191.9M | 149.9M | 193.4M | 304.2M |
| Working Capital | 1.2B | 1.0B | 1.1B | 766.1M | 566.2M |
Balance Sheet Composition
Vimta Labs Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 904.0M | 544.8M | 650.0M | 556.8M | 285.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 18.5M | 15.5M | 40.7M | 29.0M | - |
| Working Capital Changes | -95.9M | -114.0M | -76.0M | -79.3M | -184.1M |
| Operating Cash Flow | 812.6M | 430.7M | 616.4M | 503.4M | 110.7M |
| Investing Activities | |||||
| Capital Expenditures | -761.9M | -742.4M | -475.8M | -297.4M | -328.9M |
| Acquisitions | 50.3M | - | - | - | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -716.8M | -742.4M | -475.8M | -297.4M | -328.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -44.3M | -44.3M | -44.2M | -44.2M | - |
| Debt Issuance | 58.7M | 40.3M | 0 | 49.6M | 163.0M |
| Debt Repayment | -116.5M | -51.7M | -53.6M | -77.0M | -96.5M |
| Financing Cash Flow | -153.5M | -4.2M | -101.0M | -158.4M | -28.4M |
| Free Cash Flow | 151.2M | -156.8M | 381.3M | 203.4M | 40.9M |
| Net Change in Cash | -57.7M | -315.9M | 39.7M | 47.6M | -246.6M |
Cash Flow Trend
Vimta Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.76
Price to Book
5.13
Price to Sales
5.44
PEG Ratio
-1.60
Profitability Ratios
Profit Margin
18.82%
Operating Margin
23.64%
Return on Equity
17.78%
Return on Assets
14.43%
Financial Health
Current Ratio
3.30
Debt to Equity
1.63
Beta
-0.28
Per Share Data
EPS (TTM)
₹16.63
Book Value per Share
₹93.23
Revenue per Share
₹88.41
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VIMTALABS | 20.5B | 28.76 | 5.13 | 17.78% | 18.82% | 1.63 |
| Dr. Lal PathLabs | 238.9B | 46.16 | 10.20 | 22.08% | 19.84% | 6.44 |
| Sai Life Sciences | 217.1B | 64.75 | 9.48 | 7.99% | 15.34% | 18.40 |
| Krsnaa Diagnostics | 19.8B | 24.69 | 2.13 | 8.79% | 10.49% | 30.96 |
| Suraksha Diagnostic | 14.7B | 45.27 | 6.37 | 15.14% | 11.32% | 51.30 |
| Qualitek Labs | 3.6B | 37.58 | 2.57 | 12.27% | 8.97% | 50.78 |
Financial data is updated regularly. All figures are in the company's reporting currency.





